Autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells Therapy(City of Hope Medical Center)

N/A

Report date: 2025/02/10 20:00:43

Base Information

Drug NameAutologous TGF-betaR2KO/IL13R-alpha2-CAR T cells Therapy(City of Hope Medical Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTransforming growth factor beta receptor 2 modulatorsInterleukin-13 receptor subunit alpha-2 modulatorsT lymphocyte replacements
TargetsTransforming growth factor beta receptor 2Interleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastomaAstrocytoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsGlioblastomaAstrocytoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A